Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Zymeworks Inc. on December 10, 2024. The filing details the voting results for director elections, executive compensation, and auditor ratification, as well as a new non-employee director compensation policy approved by the Board on the same date.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a corporate governance report.
Material Changes and Voting Results
The following matters were voted upon by securityholders, representing approximately 79.30% of the voting power:
- Proposal 1 (Election of Directors): All four nominees were elected. Scott Platshon received the highest support at 99.60% of votes for. The other nominees received between 82.45% and 83.08% of votes for, with the remainder withheld.
- Proposal 2 (Say-on-Pay): Securityholders approved the advisory vote on executive compensation with 93.33% of votes for.
- Proposal 3 (Auditor Ratification): KPMG LLP was ratified as the independent auditor for the year ending December 31, 2024, with 96.86% of votes for.
Management Commentary and Policy Changes
The Board approved an amended non-employee director compensation policy effective immediately and January 1, 2025, to align with peer group practices:
- Cash Compensation: The annual cash retainer for Research and Development Committee members increases from $6,000 to $7,500 starting January 1, 2025. All other cash retainers remain unchanged.
- Equity Compensation (New Directors): Initial option grants for new directors are reduced from 74,000 shares to 62,000 shares, vesting monthly over 36 months.
- Equity Compensation (Continuing Directors): Annual option grants are reduced from 37,000 shares to 31,000 shares, vesting 100% at the next annual meeting.
Investor Verification Checklist
- Verify the specific vesting schedules and pro rata acceleration terms for departing directors under the new policy.
- Review the definitive proxy statement filed on October 29, 2024, for detailed biographies of the elected directors and full compensation tables.
- Confirm the impact of the reduced equity grants on total director compensation relative to peer companies.
- Note that the filing contains no financial results; refer to the most recent 10-K or 10-Q for financial health metrics.